Biogen (BIIB) Amortizatization of Intangibles (2023 - 2026)

Biogen (BIIB) recorded quarterly Amortizatization of Intangibles of $107.6 million in Q1 2026, up 42.71% quarter-over-quarter from $75.4 million in Q4 2025, and up 109.34% on a YoY basis from $51.4 million in Q1 2025.

Biogen (BIIB) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends

Biogen's Amortizatization of Intangibles history runs 4 years deep, the most recent figure standing at $107.6 million for Q1 2026.

  • In Q1 2026, Amortizatization of Intangibles rose 109.34% year-over-year to $107.6 million; the TTM figure through Mar 2026 stood at $297.0 million (up 25.16% YoY), while the FY2025 annual figure was $240.8 million, up 4.7% from the prior year.
  • Amortizatization of Intangibles was $107.6 million for Q1 2026 at Biogen, up from $75.4 million in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $107.6 million in Q1 2026 to a low of $31.5 million in Q4 2023.
  • Historically, Amortizatization of Intangibles has averaged $61.0 million across 4 years, with a median of $52.0 million in 2025.
  • The sharpest annual moves came in 2025 and 2026: Amortizatization of Intangibles tumbled 41.73% in 2025, then jumped 109.34% in 2026.
  • A 4-year view of Amortizatization of Intangibles shows it stood at $31.5 million in 2023, then jumped by 42.54% to $44.9 million in 2024, then surged by 67.93% to $75.4 million in 2025, then soared by 42.71% to $107.6 million in 2026.
  • The last three Amortizatization of Intangibles figures came in at $107.6 million (Q1 2026), $75.4 million (Q4 2025), and $61.5 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn -
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 1.70 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 931.00 Mn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 596.00 Mn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn -
10 Biogen 28.75 Bn 24.47 Bn 1.82 Bn 107.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 107.60 Mn
Mar 31, 2026 107.60 Mn
Dec 31, 2025 75.40 Mn
Dec 31, 2025 75.40 Mn
Sep 30, 2025 61.50 Mn
Sep 30, 2025 61.50 Mn
Jun 30, 2025 52.50 Mn
Jun 30, 2025 52.50 Mn
Mar 31, 2025 51.40 Mn
Mar 31, 2025 51.40 Mn
Dec 31, 2024 44.90 Mn
Dec 31, 2024 44.90 Mn
Sep 30, 2024 50.90 Mn
Sep 30, 2024 50.90 Mn
Jun 30, 2024 90.10 Mn
Jun 30, 2024 90.10 Mn
Mar 31, 2024 44.10 Mn
Mar 31, 2024 44.10 Mn
Dec 31, 2023 31.50 Mn
Dec 31, 2023 31.50 Mn